Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibuzatrelvir in Severely Immunocompromised Adults with Symptomatic COVID-19
NCT07013474Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jul 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of ibuzatrelvir in coronavirus disease 2019 (COVID-19), sponsored by Pfizer. Started Jul 2025; status: recruiting.
02
Drugs
ibuzatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07013474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07013474.